What Does Wall Street Think About AbbVie Inc. (ABBV)?

AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to invest in. On January 27, Citi cut the price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while maintaining a Neutral rating on the shares. The firm told investors that it adjusted price targets in the biopharma group as part of a Q4 preview, adding that “beatable” estimates and reduced policy risk are expected to create a favorable setup for the group in 2026.

However, Berenberg Bank lifted the price target on AbbVie Inc. (NYSE:ABBV) to $275 from $270 on January 20, reiterating a Buy rating. It updated its forecasts for the company’s Skyrizi and Rinvoq, and cited an “exceptional” growth outlook as one of the primary reasons behind the optimistic rating.

In a separate development, AbbVie Inc. (NYSE:ABBV) announced on January 16 topline results from its Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab in comparison to the investigator’s choice of chemoimmunotherapy in adult patients with relapsed/refractory diffuse large B-cell lymphoma. Epcoritamab is a T-cell-engaging bispecific antibody administered subcutaneously.

The study exhibited an improvement in progression-free survival, with improvements also observed in complete response rates, duration of response, and time to next treatment among patients treated with epcoritamab. AbbVie Inc. (NYSE:ABBV) further reported that the study did not demonstrate a statistically significant improvement in overall survival.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.